Wedbush Research Analysts Boost Earnings Estimates for COGT

Cogent Biosciences, Inc. (NASDAQ:COGT) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings per share of ($0.44) for the quarter, up from their prior forecast of ($0.47). Wedbush has a “Neutral” rating and a $11.00 price objective on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.58) EPS, FY2026 earnings at ($1.32) EPS and FY2027 earnings at ($1.00) EPS.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. increased their target price on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright lowered their target price on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cogent Biosciences has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Cogent Biosciences Price Performance

Shares of COGT opened at $6.71 on Thursday. The firm has a market cap of $741.20 million, a P/E ratio of -2.71 and a beta of 1.77. Cogent Biosciences has a 1 year low of $5.73 and a 1 year high of $12.61. The company has a 50 day simple moving average of $8.19 and a two-hundred day simple moving average of $9.56.

Institutional Trading of Cogent Biosciences

A number of institutional investors have recently bought and sold shares of COGT. FMR LLC lifted its position in Cogent Biosciences by 99.2% in the fourth quarter. FMR LLC now owns 16,569,256 shares of the technology company’s stock worth $129,240,000 after buying an additional 8,249,845 shares during the last quarter. Octagon Capital Advisors LP lifted its position in Cogent Biosciences by 111.7% in the fourth quarter. Octagon Capital Advisors LP now owns 2,763,000 shares of the technology company’s stock worth $21,551,000 after buying an additional 1,458,000 shares during the last quarter. SG Americas Securities LLC increased its stake in Cogent Biosciences by 2,865.3% in the fourth quarter. SG Americas Securities LLC now owns 964,712 shares of the technology company’s stock worth $7,525,000 after purchasing an additional 932,179 shares during the period. Walleye Capital LLC purchased a new stake in Cogent Biosciences in the third quarter worth $6,019,000. Finally, Springhill Fund Asset Management HK Co Ltd purchased a new stake in Cogent Biosciences in the fourth quarter worth $4,279,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.